Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · LENZ Therapeutics, Inc. (LENZ)

LENZ Therapeutics Q2 revenue $5.5 million; net loss widens to $31.9 million

Mixed Impact 3 of 5 earnings Written later

LENZ Therapeutics reported second-quarter 2026 results for the quarter ended June 30, 2026, with total revenue of $5.5 million, up from $5.0 million a year earlier. The net loss widened to $31.9 million, or $1.02 per share, from $14.9 million, or $0.53 per share, as selling, general and administrative expenses rose sharply to support the VIZZ launch. The filing does not include financial guidance, and the company reported $220.0 million in cash, cash equivalents and marketable securities.

Key points

  • Total revenue of $5.5 million for Q2 2026, including $1.7 million in product sales and $3.8 million in license revenue, versus $5.0 million in license revenue in Q2 2025
  • Net loss of $31.9 million, or $1.02 per share, versus $14.9 million, or $0.53 per share, in Q2 2025
  • SG&A expenses rose to $39.4 million from $12.8 million, driven by launch investment, marketing and headcount growth
  • Cash, cash equivalents and marketable securities totaled $220.0 million as of June 30, 2026

The filing

CompanyLENZ Therapeutics, Inc. (LENZ)
Form8-K, current report
Filed with the SECAug 11, 2026, 4:08 PM ET
Accession number0001815776-26-000051

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.